# The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer

> **NCT05496166** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 348 (estimated)

## Conditions studied

- Limited Stage Small Cell Lung Cancer

## Interventions

- **COMBINATION_PRODUCT:** chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy

## Key facts

- **NCT ID:** NCT05496166
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2023-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05496166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05496166, "The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05496166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*